Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Sep 1.

Published in final edited form as: Mol Carcinog. 2013 Mar 8;53(9):722–735. doi: 10.1002/mc.22024

Synergy between belinostat and gemcitabine in vitro. Panel (A) MTT assays. BxPc3 pancreatic cancer cells were cultured in 96-well plates and treated for 48 h with either gemcitabine, belinostat or the combination of both. MTT assay measured cell number relative to diluent control. A series of combination of gemcitabine and belinostat were tested. Gem 5: gemcitabine 5 μg/mL; Bel 1, 10, 100: belinostat 1, 10, 100 μM; Gem + Bel: combination of both drugs. Panel (B): Synergy between belinonstat and gemcitabine in both belinostat-sensitive and -resistant cell lines. One combination of gemcitabine and belinostat was tested. Gem, gemcitabine 5 ug/mL; Bel, belinostat 1 μM; Gem + Bel, combination of both drugs. Results represent the mean ± SD of two independent experiments with quadruplicates for each experimental and control group. Panel (C): Expression levels of ATG5, LC3, and phosphorylated p70s6k (p-p70s6k) from pancreatic cancer cell lines treated with 1 μM belinostat for 24 h were examined. Panel (D): Western blot analysis of the expression levels of LC3 and Bcl-xL were examined in cell lines treated with belinostat, gemcitabine, or the combination of both.

Synergy between belinostat and gemcitabine in vitro. Panel (A) MTT assays. BxPc3 pancreatic cancer cells were cultured in 96-well plates and treated for 48 h with either gemcitabine, belinostat or the combination of both. MTT assay measured cell number relative to diluent control. A series of combination of gemcitabine and belinostat were tested. Gem 5: gemcitabine 5 μg/mL; Bel 1, 10, 100: belinostat 1, 10, 100 μM; Gem + Bel: combination of both drugs. Panel (B): Synergy between belinonstat and gemcitabine in both belinostat-sensitive and -resistant cell lines. One combination of gemcitabine and belinostat was tested. Gem, gemcitabine 5 ug/mL; Bel, belinostat 1 μM; Gem + Bel, combination of both drugs. Results represent the mean ± SD of two independent experiments with quadruplicates for each experimental and control group. Panel (C): Expression levels of ATG5, LC3, and phosphorylated p70s6k (p-p70s6k) from pancreatic cancer cell lines treated with 1 μM belinostat for 24 h were examined. Panel (D): Western blot analysis of the expression levels of LC3 and Bcl-xL were examined in cell lines treated with belinostat, gemcitabine, or the combination of both.